Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 27 clinical trials
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX)

National trial, multicenter, randomized, phase II assessing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from

panitumumab
leucovorin
neutrophil count
irinotecan
modified folfox6
  • 17 views
  • 24 Feb, 2022
  • 1 location
Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer

This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement

EGFR
cancer
  • 1 views
  • 20 Oct, 2021
  • 1 location
FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (OPTIPRIME)

Single-arm, multi-centre phase II study The primary objective is to evaluate the time to failure of the strategy.

panitumumab
serum bilirubin level
folfox regimen
metastatic colorectal adenocarcinoma
adenocarcinoma
  • 19 views
  • 07 Apr, 2022
  • 50 locations
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

The study will use previously established doses of panitumumab or cetuximab in the metastatic setting for the treatment of unresectable colorectal cancer (CRC). It is designed to investigate an

  • 0 views
  • 27 Jun, 2021
  • 1 location
Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy (EmutRAS)

The analysis of circulating DNA (Deoxyribonucleic acid) to identify potential resistance mechanisms during anti-EGFR (epidermal growth factor receptor) treatment is of great interest, as evidenced by the recent journal published by Corcoran in the prestigious New England Journal of Medicine. EmutRAS is one of the first studies that will specifically …

EGFR
panitumumab
irinotecan
primary tumor
folfoxiri
  • 1 views
  • 25 Mar, 2022
  • 2 locations
Therascreen® KRAS RGQ PCR Kit

An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples from patients with Colorectal Cancer (CRC) who have previously tested positive for the KRAS G12C mutation for potential inclusion into the Amgen Phase III clinical trial (Protocol No 20190172) to demonstrate clinical performance …

  • 0 views
  • 14 May, 2022
  • 1 location
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)

240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg once daily (QD) and panitumumab vs investigator's choice

  • 0 views
  • 25 Jul, 2022
  • 43 locations
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (CAIRO5)

with RAS AND BRAF wildtype AND left-sided primary tumors will be randomized between doublet chemotherapy (FOLFOX or FOLFIRI) plus either bevacizumab (schedule 1) or panitumumab (schedule 3). Patient

panitumumab
primary tumor
bevacizumab
folfox regimen
metastasis
  • 249 views
  • 07 Apr, 2022
  • 50 locations
Phase II Panitumumab-IRDye800 in Head & Neck Cancer

The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of

panitumumab
carcinoma
squamous cell carcinoma
neutrophil count
  • 0 views
  • 25 Mar, 2022
  • 1 location
PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE)

The association of doublet chemotherapy (FOLFOX and FOLFIRI) and anti-EGFR-moAbs (panitumumab or cetuximab) is a standard option for the first-line treatment of unresectable RAS and BRAF wt mCRC

  • 0 views
  • 09 Aug, 2022
  • 1 location